Showing 591-600 of 3245 results for "".
Protecting Assets in a Divorce
https://practicaldermatology.com/topics/practice-management/protecting-assets-in-a-divorce/18771/Statistics show that half of marriages end in divorce. Financial consequences can be significant. OJM Group principal David Mandell, JD, MBA, discusses how physicians can protect their assets in the pre-marital and the marital stages in the event of a divorce. Always contact local counsel before taMarathon Dermatology
https://practicaldermatology.com/topics/general-topics/marathon-dermatology/20997/As the popularity of running continues to grow, dermatologists need rapid ready responses to address acute presenting problems, as well as counseling measures to help prevent recurrence.The Three-Step Journey to Your Practice Door
https://practicaldermatology.com/topics/practice-management/the-three-step-journey-to-your-practice-door/21030/Patients travel the same steps to every practice. Here's how to get them to your door.The Rising Costs of Prescription Drugs
https://practicaldermatology.com/topics/practice-management/the-rising-costs-or-prescription-drugs/18677/What's really causing the costs of dermatology prescriptions, especially generics, to skyrocket? Jake Levitt, MD and Mark Lebwohl, MD speak to host Neal Bhatia, MD about what's influencing these rising costs, and who, if anyone, is benefiting. Dr. Levitt talks about the rebate system between manufacValeant Acquires Salix; Actavis Changing Name
https://practicaldermatology.com/series/dermwire-tv/valeant-acquires-salix-actavis-changing-name/18963/Valeant expands its portfolio with the acquisition of GI market leader Salix. Actavis divests Doryx and considers a name change to Allergan. Kythera acquires rights for investigational hair therapies. And Cynosure's 532nm laser delivery system is FDA cleared for PicoSure.Otezla Approved for Plaque Psoriasis
https://practicaldermatology.com/topics/psoriasis/dermiretv-otezla-approved-for-plaque-psoriasis/19031/In this week's edition of DermWireTV from the publishers of Practical Dermatology® magazine and DermWire.com, a look at Celgene's Otezla for psoriasis--the first PDE4 inhibitor approved for plaque psoriasis. Plus, Ranbaxy's new dosage strengths of Absorica (isotretinoin), and Galderma's search for pSpend Wisely on Marketing
https://practicaldermatology.com/topics/practice-management/spend-wisely-on-marketing/19061/The best investment in marketing focuses on a long-range plan. If you have good ideas without a firm strategy and follow-through, your investment won't pay off, says Tracy Drumm, Vice President of IF Marketing.The Most Important Elements of Your Financial Plan
https://practicaldermatology.com/topics/practice-management/the-most-important-elements-of-your-financial-plan/21332/Why flexibility is crucial to meeting long-term goals.Prescribing Pitfalls, Part I: Navigate the Changing Landscape of Brand Name Drug Prescribing
https://practicaldermatology.com/topics/practice-management/prescribing-pitfalls-part-i-navigate-the-changing-landscape-of-brand-name-drug-prescribing/21440/Prescribers increasingly need to understand drug pricing, pharmacy policies, insurance coverage, and coupon offers to ensure patients get the medications they need.Rosacea: The Patient's Perspective
https://practicaldermatology.com/topics/practice-management/rosacea-the-patient-s-perspective/19263/Flor Mayoral, MD addresses the impact of rosacea on patients and offers strategies to encourage adherence. Dr. Mayoral participated in the "Face to Face with Rosacea: Empowering Professionals and Patients" event featuring actress Cynthia Nixon and supported by the National Rosacea Society and Galder